In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Votrient (Novartis)
- INDICATIONS: Advanced renal cell carcinoma
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 31 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfuzosin, Artemether/Lumefantrine, Atazanavir, BCG Vaccine, Boceprevir, Cardiac glycosides, Chloroquine, Ciprofloxacin, Clarithromycin, Clozapine, Conivaptan, CYP3A4 inducers or inhibitors, Cyproterone, Darunavir, Deferasirox, Delavirdine, Denosumab, Dronedarone, Efavirenz, Gadobutrol, Grapefruit Juice, Indacaterol, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Leflunomide, Natalizumab, Nelfinavir, Nilotinib, Oxcarbazepine, P-glycoprotein inhibitors, Pimecrolimus, Pimozide, QT prolonging agents, Quetiapine, Quinine, Rifampin, Rifapentine, Ritonavir, Roflumilast, Saquinavir, Simvastatin, Sipuleucel-T, St John's Wort, Tacrolimus, Telithromycin, Tetrabenazine, Thioridazine, Tocilizumab, Toremifene, Trastuzumab, Vaccines, Vandetanib, Vemurafenib, Vitamin K antagonists, Voriconazole, Ziprasidone
HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 12/08/2024
